SRR1331579
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.610
- INTERFERON_ALPHA_RESPONSE+0.555
- UNFOLDED_PROTEIN_RESPONSE+0.528
- INFLAMMATORY_RESPONSE+0.526
- INTERFERON_GAMMA_RESPONSE+0.515
- IL6_JAK_STAT3_SIGNALING+0.503
- MYC_TARGETS_V2+0.446
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.435
- MTORC1_SIGNALING+0.427
- UV_RESPONSE_UP+0.394
Top 10 suppressed
- E2F_TARGETS-0.314
- MITOTIC_SPINDLE-0.211
- KRAS_SIGNALING_DN-0.176
- BILE_ACID_METABOLISM-0.162
- G2M_CHECKPOINT-0.151
- PANCREAS_BETA_CELLS-0.032
- SPERMATOGENESIS-0.032
- MYOGENESIS-0.015
- HEME_METABOLISM+0.016
- PEROXISOME+0.032
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1410783 | GTEX | — | 0.929 |
| 2 | SRR1466975 | GTEX | — | 0.926 |
| 3 | SRR820133 | GTEX | — | 0.925 |
| 4 | SRR820209 | GTEX | — | 0.919 |
| 5 | 3E605854-CC65-4951-8EDB-235FD21FD71F | — | — | 0.905 |
| 6 | MNG202 | — | — | 0.899 |
| 7 | SRR1466871 | GTEX | — | 0.897 |
| 8 | TCGA-BA-A6DJ-01A-11R-A30B-07 | — | — | 0.890 |
| 9 | BS_4T0HPZDC | EPN | Posterior Fossa EPN | 0.887 |
| 10 | BS_EN2VK7NY | low-grade glioma | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.610 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.555 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.528 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.526 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.515 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.503 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.446 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.435 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.427 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.394 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.368 | Idelalisib | — uncovered |
| COMPLEMENT | 0.349 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.334 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.334 | Idelalisib | — uncovered |
| APOPTOSIS | 0.322 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.308 | Remibrutinib | — uncovered |
| HYPOXIA | 0.303 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.302 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.294 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.294 | Inavolisib | — uncovered |